EasyBlog

This is some blog description about this site

COPENHAGEN, OCTOBER 26, 2017 - AntibioTx A/S has signed a 150 M DKK (20 M EUR) financing agreement with the European Investment Bank to support late-stage clinical trials for the lead candidate ATx201. ATx201 represents a new class of antibiotics with a novel mode of action and is being developed as an innovative treatment for bacterial skin infections.

The financing agreement is supported by InnovFin - a joint initiative of the European Investment Bank and the European Commission to finance innovative healthcare projects. The financial support recognizes recent progress in AntibioTx and the potential value of the platform to respond to the immense threat from antibiotic resistance posed on global public health.

The AntibioTx platform comprises both short and long-term opportunities at the intersection of microbiology and immunology. In 2017 AntibioTx successfully completed the first clinical study and is currently conducting another five clinical studies in Phase I and Phase II on lead candidates. Data from these studies are expected in 2018.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders has been invited to present Phase I DECOLAD results at the Annual Congress of the European Academy of Dermatology and Venereology (EADV). The study enrolled 36 healthy volunteers and supported an excellent safety profile of ATx201.

The 26th EADV runs from Wednesday 13 - Sunday 17 of September 2017 in Geneva, Switzerland.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced three new board members. 

Joining AntibioTx board of directors are Stig Loekke Pedersen, Jutta Heim and Ole Skov join the board of directors in AntibioTx.

“We are very pleased to welcome such recognized business and science leaders to AntibioTx”, said Rasmus Toft-Kehler, CEO of AntibioTx and added "These profiles bring a diverse set of knowledge bases to AntibioTx - we are privileged that capacities with such track records join the team to achieve our vision”

Read more about our board of directors here

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today declared successful completion of a Phase I study with ATx201. The Study set out to determine the systemic and local exposure of three different formulations of ATx201 in 36 healthy volunteers. “We are pleased about the top-line data which show no signs of unexpected adverse events. Furthermore, pharmacokinetic data from biopsies and plasma samples are very encouraging”, said Rasmus Toft-Kehler, CEO of AntibioTx. CSO, Morten Sommer, further added “These results support the continued development of ATx201 for a variety of skin conditions including atopic dermatitis. We are thankful for the hard work and wanted to express our great appreciation to the clinicians, partners, staff, and volunteers who all contributed significantly to make this study possible”.

About the DECOLAD Phase I Study 
The DECOLAD Phase I study assessed overall safety, local tolerability, pharmacokinetics (PK) in three dermal formulations of ATx201 and was a prospective, randomized, double-blind, placebo controlled study in 36 healthy subjects. Subjects were treated at four separate skin areas, 5 cm in diameter, twice daily with either ATx201 or placebo in a 7-day period. The pharmacokinetic analysis involved blood samples in order to evaluate the systemic exposure and skin biopsies to assess local exposure to the skin. The study was conducted by the Department of Clinical Pharmacology, Medical University of Vienna, Austria.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that Antibiotx has been rewarded a grant from Innovation Fund Denmark to further explore ATx201’s influence on biomarkers in inflammatory disease.

Specific inflammatory pathways appear to be important for atopic dermatitis severity and ATx201 shows promising assets affecting these pathways. Based on this rationale, Innovation Fund Denmark has granted AntibioTx the means to investigate ATx201 in a well-established clinical model”.

About Atopic dermatitis
Atopic dermatitis is one of the most common skin diseases - it is estimated that 5–20% of the population worldwide is suffering from atopic dermatitis. The disease is believed to develop from a complex interplay of environmental and immunologic factors and is often associated with allergy and asthma. Characteristic AD symptoms are itchy skin (pruritus) and inflammation causing redness, dry skin, crusting, vesicle formation, and swelling. Numerous studies have found that AD has a major impact on physical and psychological well-being and has a negative psychological impact on close relatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Source: Thomas Bieber. Atopic Dermatitis, Mechanisms of Disease. New England Journal of Medicine, 2008

Continue reading

News